Leading International Investment Research

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Leading International Investment Research, Edison Investment Research

Equity Bottom-Up

<p>Since beginning in earnest in August this year, 1,000 prescriptions for MGC’s phytocannabinoid products (CannEpil and MXP100) have been issued in Australia and the UK. Double the number of prescriptions were issued in October compared to September. Cash receipts for the quarter ending 30 September were A$413,000, with additional revenue of more than A$400,000 from recent sales expected to be received following the end of the quarter.</p>

Since beginning in earnest in August this year, 1,000 prescriptions for MGC’s phytocannabinoid products (CannEpil and MXP100) have been issued in Australia and the UK. Double the number of prescriptions were issued in October compared to September. Cash receipts for the quarter ending 30 September were A$413,000, with additional revenue of more than A$400,000 from recent sales expected to be received following the end of the quarter.

MGC Pharmaceuticals - Rapid prescription growth in Australia and the UK

Mgc Pharmaceuticals

MGC Pharmaceuticals - Rapid prescription growth in Australia and the UK